FUSIONSPROTEINE UND KOMBINATIONSIMPFSTOFFE

European patent · EP3321287 · In force

Register entry

Publication number
EP3321287
Application number
EP17201766
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 12, 2012
Published
May 16, 2018
Granted
Feb 26, 2020
Protection ends at the latest
Apr 11, 2032
Next annual fee due
Apr 30, 2026
IPC classes
C07K 19/00 (2006.01)
A61K 39/145 (2006.01)
A61K 39/385 (2006.01)
A61P 31/16 (2006.01)
A61P 37/04 (2006.01)
C07K 14/285 (2006.01)
C12N 15/00 (2006.01)
C12P 21/02 (2006.01)
Priority
US 201161474779 P 13.04.2011
US 201161534012 P 13.09.2011
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  2. May 1, 2024

    Change

    Published in Swissreg on 01.05.2024

  3. May 1, 2023

    Change

    Published in Swissreg on 01.05.2023

  4. Feb 27, 2020

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 27.02.2020

  5. Feb 26, 2020

    Granted

    Published in Swissreg on 26.02.2020

Parties

Holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89, 1330 Rixensart, BE

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

POOLMAN, Jan

1330 Rixensart, BE

BLAIS, Normand

Laval, Québec H7V 3S8, CA

LABBE, Steve

Laval, Québec H7V 3S8, CA

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.